Galena Biopharma (GALE) Stock: Gains On Positive Trial Data


Galena Biopharma Inc (NASDAQ: GALE)

Galena Biopharma is having an overwhelmingly strong start to the trading session today, and for good reason. The company released positive data from a key clinical trial early this morning, leading to excitement among investors and gains in the stock. As is nearly always the case, our partners at Trade Ideas were the first to inform us of the gains on the stock. At the moment (9:13), GALE is trading at $0.68 per share after a gain of $0.08 per share or 14.21% thus far today.

GALE Presents Positive Data

As mentioned above, Galena Biopharma is having a strong start to the trading session this morning after presenting positive clinical data. The data came from a clinical trial surrounding NeuVax(TM) (nelipepimut-S). The trial combined NeuVax with Trastuzumab to assess the safety of the combination in high-risk HER2 3+ patients. The data proved to be overwhelmingly positive, causing the excitement that we’re seeing surrounding the stock at the moment.

Stop wasting time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping an incredibly close eye on GALE. In particular, we’re interested in following the company’s ongoing work surrounding NeuVax as the data seems to only be getting better. Nonetheless, we’ll continue to follow the story closely and bring you any updates as they break!

What Do You Think?

Where do you think GALE is headed? Join the discussion in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

[Image Courtesy of Wikimedia]

Previous articleEvoke Pharma (EVOK) Stock: Gaining Big On FDA News
Next articleStaples (SPLS) Stock: Gaining Big On Sale Exploration
Hey, Im Joshua, the founder of CNA Finance. I enjoy following the trends in the market and finding the catalysts that are making the moves. If you want to get in contact with me, leave a comment below or email me at Please keep in mind that I am not an investment advisor and nor is CNA Finance. This is a news and information gathering outlet. We may work directly with some of the companies that we write about. If we have a business relationship with an issuer, we will mention that in the articles. We also have various affiliate relationships with advertisers and may be paid if you sign up for a service that you were referred to through our website.


Please enter your comment!
Please enter your name here